Table 4.
Treatment rate ratios for chemotherapy & radiotherapy (CTRT) within 6 months of diagnosis of lung, oesophageal, pancreatic and stomach cancers in 2013–2014, from a fully adjusted multivariable model with sex, age at diagnosis, deprivation, ethnicity and Charlson comorbidity index, stratified by cancer site
| NSCLC | SCLC | Oesophagus | Stomach | Pancreas | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| %a | TRR (95% CI) | %a | TRR (95% CI) | %a | TRR (95% CI) | %a | TRR (95% CI) | %a | TRR (95% CI) | |
| Sex | ||||||||||
| Male | 12 | Ref | 31 | Ref | 9 | Ref | 4 | Ref | 1 | Ref |
| Female | 12 | 0.96 (0.90, 1.03) | 33 | 1.00 (0.90, 1.10) | 6 | 0.82 (0.63, 1.07) | 3 | 0.63 (0.42, 0.95) | 1 | 1.06 (0.71, 1.57) |
| p for heterogeneityb | 0.22 | 0.93 | 0.15 | 0.03 | 0.79 | |||||
| Age at cancer diagnosis | ||||||||||
| <50 | 29 | 1.52 (1.33, 1.74) | 50 | 1.31 (1.03, 1.66) | 10 | 0.87 (0.52, 1.44) | 9 | 1.69 (1.00, 2.85) | 3 | 1.77 (0.86, 3.63) |
| 50 – 59 | 25 | 1.36 (1.25, 1.49) | 47 | 1.26 (1.10, 1.43) | 14 | 1.37 (1.03, 1.82) | 5 | 1.04 (0.60, 1.78) | 3 | 2.07 (1.24, 3.48) |
| 60 – 69 | 18 | Ref | 39 | Ref | 10 | Ref | 5 | Ref | 2 | Ref |
| 70 – 79 | 9 | 0.53 (0.49, 0.58) | 25 | 0.59 (0.53, 0.67) | 7 | 0.75 (0.57, 0.98) | 3 | 0.56 (0.35, 0.88) | 1 | 0.77 (0.45, 1.32) |
| 80+ | 2 | 0.11 (0.10, 0.13) | 11 | 0.28 (0.22, 0.35) | 2 | 0.24 (0.14, 0.40) | 1 | 0.26 (0.13, 0.51) | 0 | 0.28 (0.12, 0.68) |
| p for heterogeneityb | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | |||||
| Charlson comorbidity index | ||||||||||
| 0 | 13 | Ref | 34 | Ref | 9 | Ref | 4 | Ref | 2 | Ref |
| 1 | 8 | 0.73 (0.65, 0.83) | 28 | 0.88 (0.75, 1.04) | 9 | 1.27 (0.88, 1.83) | 3 | 0.93 (0.50, 1.74) | 2 | 1.19 (0.66, 2.14) |
| 2 | 7 | 0.71 (0.60, 0.84) | 27 | 0.92 (0.74, 1.14) | 5 | 0.76 (0.41, 1.44) | 3 | 1.06 (0.49, 2.30) | 1 | 0.66 (0.21, 2.11) |
| 3+ | 3 | 0.35 (0.27, 0.45) | 15 | 0.50 (0.36, 0.70) | 4 | 0.71 (0.33, 1.51) | 2 | 0.80 (0.25, 2.55) | 0 | 0.27 (0.04, 1.92) |
| p for heterogeneityb | <0.0001 | 0.0004 | 0.33 | 0.98 | 0.45 | |||||
| Deprivation quintile | ||||||||||
| 1: least deprived | 13 | Ref | 32 | Ref | 11 | Ref | 4 | Ref | 2 | Ref |
| 2 | 13 | 0.98 (0.88, 1.10) | 32 | 0.91 (0.76, 1.09) | 9 | 0.86 (0.63, 1.19) | 3 | 0.93 (0.52, 1.66) | 2 | 1.00 (0.56, 1.77) |
| 3 | 11 | 0.86 (0.77, 0.96) | 35 | 1.03 (0.87, 1.23) | 7 | 0.70 (0.50, 0.98) | 4 | 1.16 (0.67, 2.01) | 1 | 0.71 (0.38, 1.33) |
| 4 | 11 | 0.82 (0.74, 0.92) | 31 | 0.87 (0.73, 1.03) | 8 | 0.71 (0.51, 0.99) | 4 | 0.96 (0.55, 1.69) | 1 | 1.00 (0.55, 1.82) |
| 5: most deprived | 11 | 0.77 (0.69, 0.85) | 30 | 0.81 (0.68, 0.96) | 7 | 0.61 (0.43, 0.87) | 3 | 0.90 (0.50, 1.62) | 1 | 0.84 (0.44, 1.63) |
| p for heterogeneityb | <0.0001 | 0.009 | 0.04 | 0.91 | 0.79 | |||||
| Ethnicity | ||||||||||
| White | 12 | Ref | 32 | Ref | 8 | Ref | 4 | Ref | 1 | Ref |
| Non-white | 18 | 1.16 (1.01, 1.33) | 31 | 0.83 (0.59, 1.15) | 10 | 1.24 (0.64, 2.43) | 5 | 1.08 (0.59, 1.97) | 1 | 0.39 (0.12, 1.26) |
| Unknown | 8 | 0.67 (0.55, 0.83) | 21 | 0.73 (0.51, 1.05) | 3 | 0.39 (0.16, 0.95) | 2 | 0.53 (0.13, 2.16) | 1 | 0.46 (0.11, 1.88) |
| p for heterogeneityb | 0.0001 | 0.13 | 0.09 | 0.65 | 0.17 | |||||
CI confidence interval, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, TRR treatment rate ratio.
a Proportion of patients recorded to receive treatment in each category.
b Performed jointly across all categories of each variable, using a post-estimation Wald test